ANIMAL LENTIVIRUSES--STRATEGIES FOR HIV VACCINATION
- Peter F Buckley(PI),
- Scott Mader(PI),
- Michael Maes(PI),
- Vicent Monnier(PI),
- John T. Carey(PI),
- Paula Silverman(PI)
- ,
- UNIVERSITY HOSPITALS OF CLEVELAND,
- CASE WESTERN RESERVE UNIVERSITY,
- CASE WESTERN RESERVE UNIVERSITY,
- UNIVERSITY HOSPITALS OF CLEVELAND,
- CASE WESTERN RESERVE UNIVERSITY
Grant:
Research project
Project status
Finished
About the Project
The human imunodeficiency virus (HIV) is a member of the lentivirus<br/>subfamily, a taxonomic group of nononcogenic retroviruses that<br/>persistently infect cells of the host immune system. These are<br/>enveloped viruses that have a highly glycosylated envelope glycoprotein<br/>(env gp) that stimulates strong immune responses in the infected host.<br/>However, immune responses elicited during natural infection fail to<br/>control virus replication resulting in a persistent infection that<br/>eventually leads to chronic multisystemic disease and death. Many of<br/>the functional domains that mediate cell tropism, cytopathicity, and<br/>neutralization of virus by antibody have been mapped to the env gp of<br/>HIV. However, the properties of the lentivirus envelope that underlie<br/>ineffective anti-lentivirus immune responses are poorly understood and<br/>difficult to evaluate with HIV itself. Insight into these areas are<br/>essential to developing effective immune based strategies against HIV.<br/>Caprine arthritis encephalitis virus (CAEV) of goats and visna virus of<br/>sheep are two closely related, well-characterized lentiviruses that<br/>mirror HIV in many of their biological and structural characteristics.<br/>Infectious molecular clones of both CAEV and visna that have been<br/>completely sequenced are available for study and provide a system in<br/>which to address questions of lentivirus immunogenicity and pathogenesis<br/>in the natural host. This proposal focuses on mapping and<br/>characterizing the functional domains of the ovine/caprine lentivirus<br/>env gp. A set of truncated and mutated env gp genes will be constructed<br/>using the polymerase chain reaction with synthetic oligonucleotides as<br/>primers and the subcloned into a baculovirus expression vector.<br/>Recombinant baculovirus expressing the various forms of the env gp will<br/>be used to infect spinner flasks of insect cells to obtain milligram<br/>quantities of purified env gp. The various purified glycoprotein<br/>constructs will be compared for their ability to block in various<br/>functional assays. In years 4-5 these mapping studies will be extended<br/>by using PCR to construct infectious molecular clones that are envelope<br/>chimeras of CAEV and visna. Switching specific domains between the env<br/>genes of the two viruses will map determinants of cell tropism, antibody<br/>neutralization, immunogenicity and pathogenicity for the ovine/caprine<br/>lentiviruses in their natural host. These biological properties are<br/>mediated at least in part by env gp and differ markedly between the well<br/>characterized parental viruses, CAEV and visna virus. The candidate has limited experience in applying techniques of molecular<br/>biology to the study of disease pathogenesis. The supervisor is a<br/>recognized expert in the field of lentivirus molecular biology with a<br/>large active lab. The candidate has been provided with independent<br/>laboratory space at the Bayview Research Campus of the Johns Hopkins<br/>University, School of Medicine along with equipment and support from the<br/>Division of Comparative Medicine and the university. This combination<br/>of factors should provide an excellent environment for completing the<br/>proposed studies and greatly enhance the candidate's development as an<br/>independent researcher.
Project Information
Project Type
Research project
Project Managed By
Time Period
12/01/1978 – 03/31/2009Status
FinishedFunding Details
SERTINDOLE AND RISPERIDONE IN TREATMENT RESISTANT SCHIZOPHRENIC PATIENTSRenewal
FunderAmount
National Institutes of Health
0 USDSERTINDOLE AND RISPERIDONE IN TREATMENT RESISTANT SCHIZOPHRENIC PATIENTSRenewal
FunderAmount
National Institutes of Health
0 USDSERTINDOLE AND RISPERIDONE IN TREATMENT RESISTANT SCHIZOPHRENIC PATIENTSRenewal
FunderAmount
National Institutes of Health
0 USDSERTINDOLE AND RISPERIDONE IN TREATMENT RESISTANT SCHIZOPHRENIC PATIENTSRenewal
FunderAmount
National Institutes of Health
0 USD